[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 71,059,696
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,629 M
  • EBITDA $ 4,173 M
  • 60-Month Beta 0.24
  • Price/Sales 4.99
  • Price/Cash Flow 16.12
  • Price/Book 2.28

Options Overview Details

View History
  • Implied Volatility 37.68% (+1.53%)
  • Historical Volatility 26.37%
  • IV Percentile 65%
  • IV Rank 50.28%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 3) 17.60 (2.62%)
  • Put/Call Vol Ratio 1.65
  • Today's Volume 2,765
  • Volume Avg (30-Day) 1,132
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 36,412
  • Open Int (30-Day) 37,039
  • Expected Range 654.87 to 690.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.00
  • Number of Estimates 6
  • High Estimate $10.21
  • Low Estimate $5.66
  • Prior Year $10.72
  • Growth Rate Est. (year over year) -25.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
594.90 +13.12%
on 06/22/26
691.13 -2.63%
on 07/17/26
+63.00 (+10.33%)
since 06/18/26
3-Month
591.52 +13.76%
on 06/02/26
767.21 -12.29%
on 04/23/26
-74.42 (-9.96%)
since 04/21/26
52-Week
541.00 +24.39%
on 10/13/25
821.11 -18.05%
on 01/09/26
+127.41 (+23.36%)
since 07/21/25

Most Recent Stories

More News
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN

NEW YORK , July 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).

REGN : 675.62 (+0.52%)
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN

LOS ANGELES , July 20, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: ...

REGN : 675.62 (+0.52%)
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , July 20, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals,...

REGN : 675.62 (+0.52%)
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN

The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN ) violations of §§10(b)...

REGN : 675.62 (+0.52%)
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ:...

REGN : 675.62 (+0.52%)
Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May...

REGN : 675.62 (+0.52%)
1 Large-Cap Stock with Exciting Potential and 2 We Turn Down

1 Large-Cap Stock with Exciting Potential and 2 We Turn Down

BSX : 43.10 (-1.53%)
CNC : 67.22 (+2.10%)
REGN : 675.62 (+0.52%)
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its second quarter 2026 financial and operating results on Thursday,...

REGN : 675.62 (+0.52%)
The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

APGE : 134.27 (+0.09%)
JNJ : 249.92 (+0.44%)
LLY : 1,166.52 (+1.71%)
ABBV : 256.05 (+1.05%)
REGN : 675.62 (+0.52%)
SNY : 43.76 (-0.50%)
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target...

REGN : 675.62 (+0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 691.16
2nd Resistance Point 686.45
1st Resistance Point 679.30
Last Price 675.62
1st Support Level 667.44
2nd Support Level 662.73
3rd Support Level 655.58

See More

52-Week High 821.11
Fibonacci 61.8% 714.11
Fibonacci 50% 681.05
Last Price 675.62
Fibonacci 38.2% 648.00
52-Week Low 541.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.